Treatment With Anakinra, a Recombinant IL-1 Receptor Antagonist, Unlikely to Induce Lasting Remission in Patients With CGD Colitis

Am J Gastroenterol. 2015 Jun;110(6):938-9. doi: 10.1038/ajg.2015.135.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Adolescent
  • Adult
  • Antirheumatic Agents / therapeutic use*
  • Child
  • Colitis / drug therapy*
  • Colitis / etiology
  • Female
  • Granulomatous Disease, Chronic / complications
  • Granulomatous Disease, Chronic / drug therapy*
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*
  • Maintenance Chemotherapy
  • Male
  • Remission Induction
  • Retrospective Studies
  • Treatment Outcome
  • Young Adult

Substances

  • Antirheumatic Agents
  • Interleukin 1 Receptor Antagonist Protein